tetano
Editor, Senior Moderator
J Clin Med
. 2021 Dec 26;11(1):116.
doi: 10.3390/jcm11010116.
Association between Nafamostat Mesylate and In-Hospital Mortality in Patients with Coronavirus Disease 2019: A Multicenter Observational Study
Ryota Inokuchi[SUP] 1 [/SUP], Toshiki Kuno[SUP] 2 [/SUP], Jun Komiyama[SUP] 1 3 [/SUP], Kazuaki Uda[SUP] 4 [/SUP], Yoshihisa Miyamoto[SUP] 5 [/SUP], Yuta Taniguchi[SUP] 3 4 [/SUP], Toshikazu Abe[SUP] 1 6 [/SUP], Miho Ishimaru[SUP] 1 [/SUP], Motohiko Adomi[SUP] 1 4 [/SUP], Nanako Tamiya[SUP] 1 4 [/SUP], Masao Iwagami[SUP] 1 4 [/SUP]
Affiliations
Abstract
Nafamostat mesylate may be effective against coronavirus disease 2019 (COVID-19). However, it is not known whether its use is associated with reduced in-hospital mortality in clinical practice. We conducted a retrospective observational study to evaluate the effect of nafamostat mesylate in patients with COVID-19 using the Medical Data Vision Co. Ltd. hospital-based database in Japan. We compared patients with COVID-19 who were (n = 121) and were not (n = 15,738) administered nafamostat mesylate within 2 days of admission between January and December 2020. We conducted a 1:4 propensity score matching with multiple imputations for smoking status and body mass index and combined the 20 imputed propensity score-matched datasets to obtain the adjusted odds ratio for in-hospital mortality. Crude in-hospital mortality was 13.2% (16/121) and 5.0% (790/15,738), respectively. In the propensity score-matched analysis with multiple imputations, the adjusted odds ratio (use vs. no use of nafamostat mesylate) for in-hospital mortality was 1.27 (95% confidence interval: 0.61-2.64; p = 0.52). Sensitivity analyses showed similar results. The results of this retrospective observational study did not support an association between nafamostat mesylate and improved in-hospital outcomes in patients with COVID-19, although further studies with larger sample sizes are warranted to assess the generalizability of our findings.
Keywords: coronavirus disease 2019; in-hospital mortality; nafamostat mesylate.
. 2021 Dec 26;11(1):116.
doi: 10.3390/jcm11010116.
Association between Nafamostat Mesylate and In-Hospital Mortality in Patients with Coronavirus Disease 2019: A Multicenter Observational Study
Ryota Inokuchi[SUP] 1 [/SUP], Toshiki Kuno[SUP] 2 [/SUP], Jun Komiyama[SUP] 1 3 [/SUP], Kazuaki Uda[SUP] 4 [/SUP], Yoshihisa Miyamoto[SUP] 5 [/SUP], Yuta Taniguchi[SUP] 3 4 [/SUP], Toshikazu Abe[SUP] 1 6 [/SUP], Miho Ishimaru[SUP] 1 [/SUP], Motohiko Adomi[SUP] 1 4 [/SUP], Nanako Tamiya[SUP] 1 4 [/SUP], Masao Iwagami[SUP] 1 4 [/SUP]
Affiliations
- PMID: 35011857
- DOI: 10.3390/jcm11010116
Abstract
Nafamostat mesylate may be effective against coronavirus disease 2019 (COVID-19). However, it is not known whether its use is associated with reduced in-hospital mortality in clinical practice. We conducted a retrospective observational study to evaluate the effect of nafamostat mesylate in patients with COVID-19 using the Medical Data Vision Co. Ltd. hospital-based database in Japan. We compared patients with COVID-19 who were (n = 121) and were not (n = 15,738) administered nafamostat mesylate within 2 days of admission between January and December 2020. We conducted a 1:4 propensity score matching with multiple imputations for smoking status and body mass index and combined the 20 imputed propensity score-matched datasets to obtain the adjusted odds ratio for in-hospital mortality. Crude in-hospital mortality was 13.2% (16/121) and 5.0% (790/15,738), respectively. In the propensity score-matched analysis with multiple imputations, the adjusted odds ratio (use vs. no use of nafamostat mesylate) for in-hospital mortality was 1.27 (95% confidence interval: 0.61-2.64; p = 0.52). Sensitivity analyses showed similar results. The results of this retrospective observational study did not support an association between nafamostat mesylate and improved in-hospital outcomes in patients with COVID-19, although further studies with larger sample sizes are warranted to assess the generalizability of our findings.
Keywords: coronavirus disease 2019; in-hospital mortality; nafamostat mesylate.